Lenvatinib Plus PD-1 Antibody for Unresectable ICC
- Status
- SUSPENDED
- Phase
- PHASE2
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria
- Status
- WITHDRAWN
- Phase
- PHASE2
HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
- Status
- UNKNOWN
- Phase
- PHASE3
Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
- Status
- WITHDRAWN
- Phase
- PHASE2
Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC
- Status
- WITHDRAWN
- Phase
- PHASE3
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Status
- COMPLETED
- Phase
- PHASE3
A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- N/A
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Lenvatinib and Pembrolizumab Simultaneous Combination Study
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer
- Status
- COMPLETED
- Phase
- PHASE4
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
- Status
- COMPLETED
- Phase
- PHASE1
Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- Status
- RECRUITING
- Phase
- PHASE3
Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1